НИВА НА СЕРУМЕН C-ПЕПТИД ПРИ НОВОДИАГНОСТИЦИРАНИ С ДИАБЕТ ВЪЗРАСТНИ ПАЦИЕНТИ: КРОССЕКЦИОННО ПРОУЧВАНЕ ОТ ЮЖНА ИНДИЯ
Ключови думи :
serum C-peptide, newly diagnosed diabetes, beta-cell function, autoantibodies, South Asian population, diabetes heterogeneity, autoimmune diabetes, LADA, beta-cell reserve, glucagon stimulation testАбстракт
Background: Accurate assessment of pancreatic beta-cell function in diabetes diagnosis is important for
prognosis and individualized management. C-peptide is a reliable biomarker of endogenous insulin secretion, but data from treatment-naïve South Asian adults are limited. Materials and Methods: Single-center cross-sectional study in Salem, South India, including 100 adults (18-70 years) with newly diagnosed diabetes (< 6 months) and minimal treatment exposure. Fasting and glucagon-stimulated serum C-peptide were measured, with clinical and metabolic profiling and targeted autoantibody testing when indicated. Results: Mean fasting C-peptide was 1.62 ± 0.72 ng/mL and stimulated C-peptide was 2.53 ± 1.01 ng/mL. Low β-cell reserve (< 0.8 ng/mL fasting and/or < 1.8 ng/mL stimulated) was present in 29%. C-peptide showed no clinically meaningful correlation with HbA1c, fasting glucose, BMI, or HOMA indices. Subtype classification suggested 65% T2D-like, 21% possible autoimmune (LADA), and 14% indeterminate. Conclusions: Adults with newly diagnosed diabetes in South India show substantial heterogeneity in β-cell reserve, with nearly one-third having low C-peptide at presentation. Integrating C-peptide (and selective autoantibody testing)
may improve early clinical stratification.
Литература (библиография)
Spanning the Range from Normal Glucose Tolerance to Overt Diabetes: A New Analysis. The Journal of Clinical Endocrinology & Metabolism, 2005, 90(1), 493-500. DOI: 10.1210/jc.2004-1133.
Holman RR, Paul SK, Bethel MA, et al. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. The New England Journal of Medicine, 2008, 359(15), 1577-1589. DOI: 10.1056/NEJMoa0806470. [UKPDS key data 1990s-2004]
Bonora E, Calcaterra F, Lombardi S, et al. Beta-cell Function and Insulin Sensitivity in Subjects with Impaired Fasting Glucose. European Journal of Clinical Investigation, 2006, 31(5), 380-386.
Steffes MW, Sibley S, Jackson MI, Thomas W. Beta-cell Function and the Development of Diabetes-related Complications in the Diabetes Control and Complications Trial. Diabetes Care, 2003, 26(3), 832-836. DOI: 10.2337/diacare.26.3.832.
DCCT Research Group. Beta-cell Function and Serum Lipid Concentrations are Independent Predictors. Diabetes Care, 1995, 18(12),1642-1649.
Zavaroni I, Deferrari G, Lugari R, et al. Renal metabolism of C-peptide in man. J Clin Endocrinol Metab. 1987;65:494-498.
Kjems LL, Christiansen E, Vølund A, et al. Validation of methods for measurement of insulin secretion in humans in vivo. Diabetes. 2000;49:580-588.
Polonsky KS, Given BD, Hirsch LJ, et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med. 1988;318:1231-1239.
Takabe M, Matsuda T, Hirota Y, et al. C-peptide response to glucagon challenge is correlated with improvement of early insulin secretion by liraglutide treatment. Diabetes Res Clin Pract. 2012;98:e32-e35.
Leighton E, Sainsbury CA, Jones GC. A practical review of C-peptide testing in diabetes. Diabetes Ther. 2017;8:475-487.
Maddaloni E, Bolli GB, Frier BM, et al. C-peptide determination in the diagnosis of type of diabetes and its management: a clinical perspective. Diabetes Obes Metab. 2022;24:1912-1926.
McDonald TJ, Knight BA, Shields BM, et al. Stability and reproducibility of a single-sample urinary C-peptide/creatinine ratio and its correlation with 24-h urinary C-peptide. Clin Chem. 2009;55:2035-2039.
Bowman P, McDonald TJ, Shields BM, et al. Validation of a single-sample urinary C-peptide creatinine ratio as a reproducible alternative to serum C-peptide in patients with Type 2 diabetes. Diabet Med. 2012;29:90-93.
Shepherd M, Shields B, Hammersley S, et al. Systematic population screening, using biomarkers and genetic testing, identifies 2.5% of the U.K. pediatric diabetes population with monogenic diabetes. Diabetes Care. 2016;39:1879-1888.
Shields BM, Shepherd M, Hudson M, et al. Population-based assessment of a biomarker-based screening pathway to aid diagnosis of monogenic diabetes in young-onset patients. Diabetes Care. 2017;40:1017-1025.
Huttunen NP, Knip M, Käär ML, et al. Clinical significance of urinary C-peptide excretion in children with insulin-dependent diabetes mellitus. Acta Paediatr Scand. 1989;78:271-277.
Gerö L, Korányi L, Tamás G Jr. Residual B-cell function in insulin dependent (Type 1) and non insulin-dependent (Type 2) diabetics (relationship between 24-h C-peptide excretion and the clinical features of diabetes). Diabetes Metab. 1983;9:183-187.
Rao PV, Bean E, Nair-Schaef D, et al. Rapid point-of-care test for determination of C-peptide levels. J Diabetes Sci Technol. 2022;16:976-981.
McDonald TJ, Perry MH, Peake RW, et al. EDTA improves stability of whole blood C-peptide and insulin to over 24 h at room temperature.PLoS One. 2012;7:e42084.
Oddoze C, Lombard E, Portugal H. Stability study of 81 analytes in human whole blood, in serum and in plasma. Clin Biochem. 2012;45:464-469.
Nkuna DX, Khoza SP, George JA, et al. The stability of C-peptide and insulin in plasma and serum samples under different storage conditions. Clin Chem Lab Med. 2023;61:2150-2158.
Greenbaum CJ, Mandrup-Poulsen T, McGee PF, et al. Mixedmeal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care. 2008;31:1966-1971.
Besser RE, Jones AG, McDonald TJ, et al. The impact of insulin administration during the mixed meal tolerance test. Diabet Med. 2012;29:1279-1284.
Hope SV, Knight BA, Shields BM, et al. Random nonfasting C-peptide: bringing robust assessment of endogenous insulin secretion to the clinic. Diabet Med. 2016;33:1554-1558.
Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med. 2013;30:803-817.
Файлове за сваляне
Публикуван
Брой
Раздел (Секция)
Лиценз
Авторски права (c) 2026 V. Digraj , P. Selvam (Author)
Публикация с Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Можете свободно да споделяте, копирате и разпространявате материала във всякакъв носител или формат при следните условия.
